{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T18:31:25Z","timestamp":1775932285646,"version":"3.50.1"},"reference-count":48,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2024]]},"DOI":"10.3960\/jslrt.23047","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T22:15:43Z","timestamp":1711577743000},"page":"10-20","source":"Crossref","is-referenced-by-count":3,"title":["Complex karyotype determined using conventional cytogenetic analysis                    is a poor prognostic factor in patients with multiple myeloma"],"prefix":"10.3960","volume":"64","author":[{"given":"Hideki","family":"Uryu","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Shirouchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhito","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukako","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kikuaki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Perrot                            A,                                Lauwers-Cances                            V,                                Cazaubiel                            T                    <i>et al.<\/i> Early versus late autologous stem cell transplant in                    newly diagnosed multiple myeloma: Long-term follow-up analysis of the IFM 2009                    trial. Blood. 2020; 136: 39.","DOI":"10.1182\/blood-2020-134538"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Durie                            BGM,                                Hoering                            A,                                Sexton                            R                    <i>et al.<\/i> Longer term follow-up of the randomized phase III trial                    SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and                    dexamethasone in patients (Pts) with previously untreated multiple myeloma                    without an intent for immediate autologous stem cell transplant (ASCT). Blood                    Cancer J. 2020; 10: 53.","DOI":"10.1038\/s41408-020-0311-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Facon                            T,                                Kumar                            S,                                Plesner                            T                    <i>et al.<\/i> Daratumumab plus lenalidomide and dexamethasone for                    untreated myeloma. N Engl J Med. 2019; 380: 2104-2115.","DOI":"10.1056\/NEJMoa1817249"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Mateos                            MV,                                Dimopoulos                            MA,                                Cavo                            M                    <i>et al.<\/i> Daratumumab plus bortezomib, melphalan, and prednisone                    for untreated myeloma. N Engl J Med. 2018; 378: 518-528.","DOI":"10.1056\/NEJMoa1714678"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Facon                            T,                                Kumar                            SK,                                Plesner                            T                    <i>et al.<\/i> Daratumumab, lenalidomide, and dexamethasone versus                    lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA):                    overall survival results from a randomised, open-label, phase 3 trial. Lancet                    Oncol. 2021; 22: 1582-1596.","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Fonseca                            R,                                Bergsagel                            PL,                                Drach                            J                    <i>et al.<\/i> International Myeloma Working Group molecular                    classification of multiple myeloma: spotlight review. Leukemia. 2009; 23:                    2210-2221.","DOI":"10.1038\/leu.2009.174"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Ross                            FM,                                Avet-Loiseau                            H,                                Ameye                            G                    <i>et al.<\/i> Report from the European Myeloma Network on interphase                    FISH in multiple myeloma and related disorders. Haematologica. 2012; 97:                    1272-1277.","DOI":"10.3324\/haematol.2011.056176"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Palumbo                            A,                                Avet-Loiseau                            H,                                Oliva                            S                    <i>et al.<\/i> Revised International Staging System for multiple                    myeloma: A report from International Myeloma Working Group. J Clin Oncol. 2015;                    33: 2863-2869.","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Walker                            BA,                                Leone                            PE,                                Chiecchio                            L                    <i>et al.<\/i> A compendium of myeloma-associated chromosomal copy                    number abnormalities and their prognostic value. Blood. 2010; 116:                    e56-e65.","DOI":"10.1182\/blood-2010-04-279596"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Avet-Loiseau                            H,                                Attal                            M,                                Campion                            L                    <i>et al.<\/i> Long-term analysis of the IFM 99 trials for myeloma:                    cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in                    defining long-term survival. J Clin Oncol. 2012; 30: 1949-1952.","DOI":"10.1200\/JCO.2011.36.5726"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Schmidt                            TM,                                Barwick                            BG,                                Joseph                            N                    <i>et al.<\/i> Gain of Chromosome 1q is associated with early                    progression in multiple myeloma patients treated with lenalidomide, bortezomib,                    and dexamethasone. Blood Cancer J. 2019; 9: 94.","DOI":"10.1038\/s41408-019-0254-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Abdallah                            N,                                Greipp                            P,                                Kapoor                            P                    <i>et al.<\/i> Clinical characteristics and treatment outcomes of newly                    diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020; 4:                    3509-3519.","DOI":"10.1182\/bloodadvances.2020002218"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 D\u2019Agostino                            M,                                Cairns                            DA,                                Lahuerta                            JJ                    <i>et al.<\/i> Second revision of the International Staging System                    (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network                    (EMN) Report within the HARMONY Project. J Clin Oncol. 2022; 40:                    3406-3418.","DOI":"10.1200\/JCO.22.02228"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Carballo-Zarate                            AA,                                Medeiros                            LJ,                                Fang                            L                    <i>et al.<\/i> Additional-structural-chromosomal aberrations are                    associated with inferior clinical outcome in patients with hyperdiploid multiple                    myeloma: a single-institution experience. Mod Pathol. 2017; 30:                    843-853.","DOI":"10.1038\/modpathol.2017.3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Van                                Wier                            S,                                Braggio                            E,                                Baker                            A                    <i>et al.<\/i> Hypodiploid multiple myeloma is characterized by more                    aggressive molecular markers than non-hyperdiploid multiple myeloma.                    Haematologica. 2013; 98: 1586-1592.","DOI":"10.3324\/haematol.2012.081083"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Hebraud                            B,                                Magrangeas                            F,                                Cleynen                            A                    <i>et al.<\/i> Role of additional chromosomal changes in the prognostic                    value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood.                    2015; 125: 2095-2100.","DOI":"10.1182\/blood-2014-07-587964"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Rajkumar                            SV,                                Dimopoulos                            MA,                                Palumbo                            A                    <i>et al.<\/i> International Myeloma Working Group updated criteria for                    the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15:                    e538-e548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Durie                            BGM,                                Harousseau                            JL,                                Miguel                            JS                    <i>et al.<\/i> International uniform response criteria for multiple                    myeloma. Leukemia. 2006; 20: 1467-1473.","DOI":"10.1038\/sj.leu.2404284"},{"key":"19","unstructured":"19 Inazawa J, Abe T. [Clinical FISH Protocol:                    Visible chromosome and genetic diagnostics] Rinsho FISH purotocoru: Me de miru                    senshokutai idenshi shindanhou (in Japanese). Tokyo, Shujunsha. 1997; pp.                    1-204."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Seabright                            M. A rapid                    banding technique for human chromosomes. Lancet. 1971; 298:                    971-972.","DOI":"10.1016\/S0140-6736(71)90287-X"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 McGowan-Jordan J, Hastings RJ, Moore S. ISCN                    2020: An International System for Human Cytogenomic Nomenclature (2020). 1st ed,                    Basel, Karger. 2020.","DOI":"10.1159\/isbn.978-3-318-06867-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Nguyen-Khac                            F,                                Bidet                            A,                                Daudignon                            A                    <i>et al.<\/i> The complex karyotype in hematological malignancies: a                    comprehensive overview by the Francophone Group of Hematological Cytogenetics                    (GFCH). Leukemia. 2022; 36: 1451-1466.","DOI":"10.1038\/s41375-022-01561-w"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Kanda                            Y. Investigation                    of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone                    Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Smadja                            NV,                                Bastard                            C,                                Brigaudeau                            C,                                Leroux                            D,                                Fruchart                            C. Hypodiploidy                    is a major prognostic factor in multiple myeloma. Blood. 2001; 98:                    2229-2238.","DOI":"10.1182\/blood.V98.7.2229"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Hao                            S,                                Lin                            P,                                Medeiros                            LJ                    <i>et al.<\/i> Clinical implications of cytogenetic heterogeneity in                    multiple myeloma patients with TP53 deletion. Mod Pathol. 2017; 30:                    1378-1386.","DOI":"10.1038\/modpathol.2017.63"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Hao                            S,                                Lu                            X,                                Gong                            Z                    <i>et al.<\/i> The survival impact of CKS1B gains or amplification is                    dependent on the background karyotype and TP53 deletion status in patients with                    myeloma. Mod Pathol. 2021; 34: 327-335.","DOI":"10.1038\/s41379-020-00669-7"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Obiekwe                            D,                                Joseph                            N,                                Hofmeister                            CC                    <i>et al.<\/i> The impact of complex karyotype identified by                    conventional cytogenetics on survival outcomes of 1,000 patients with newly                    diagnosed myeloma (NDMM). J Clin Oncol. 2022; 40: 8063-8063.","DOI":"10.1200\/JCO.2022.40.16_suppl.8063"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Lim                            JH,                                Seo                            EJ,                                Park                            CJ                    <i>et al.<\/i> Cytogenetic classification in Korean multiple myeloma                    patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and                    the number of structural abnormalities. Eur J Haematol. 2014; 92:                    313-320.","DOI":"10.1111\/ejh.12257"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Rajkumar                            SV,                                Larson                            D,                                Kyle                            RA. Diagnosis of                    smoldering multiple myeloma. N Engl J Med. 2011; 365: 474-475.","DOI":"10.1056\/NEJMc1106428"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Al                                Saleh                            AS,                                Parmar                            HV,                                Visram                            A                    <i>et al.<\/i> Increased bone marrow plasma-cell percentage predicts                    outcomes in newly diagnosed multiple myeloma patients. Clin Lymphoma Myeloma                    Leuk. 2020; 20: 596-601.","DOI":"10.1016\/j.clml.2020.03.012"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Merz                            M,                                Hielscher                            T,                                Seckinger                            A                    <i>et al.<\/i> Baseline characteristics, chromosomal alterations, and                    treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Am J                    Hematol. 2016; 91: E473-E477.","DOI":"10.1002\/ajh.24533"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Hu                            X,                                Wu                            CH,                                Cowan                            JM,                                Comenzo                            RL,                                Varga                            C. Outcomes of                    patients with multiple myeloma harboring chromosome 1q gain\/amplification in the                    era of modern therapy. Ann Hematol. 2022; 101: 369-378.","DOI":"10.1007\/s00277-021-04704-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Hose                            D,                                R\u00e8me                            T,                                Hielscher                            T                    <i>et al.<\/i> Proliferation is a central independent prognostic factor                    and target for personalized and risk-adapted treatment in multiple myeloma.                    Haematologica. 2011; 96: 87-95.","DOI":"10.3324\/haematol.2010.030296"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Mellors                            PW,                                Binder                            M,                                Ketterling                            RP                    <i>et al.<\/i> Metaphase cytogenetics and plasma cell proliferation                    index for risk stratification in newly diagnosed multiple myeloma. Blood Adv.                    2020; 4: 2236-2244.","DOI":"10.1182\/bloodadvances.2019001275"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Corre                            J,                                Montes                            L,                                Martin                            E                    <i>et al.<\/i> Early relapse after autologous transplant for myeloma is                    associated with poor survival regardless of cytogenetic risk. Haematologica.                    2020; 105: e480-e483.","DOI":"10.3324\/haematol.2019.236588"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Shah                            V,                                Sherborne                            AL,                                Walker                            BA                    <i>et al.<\/i> Prediction of outcome in newly diagnosed myeloma: a                    meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;                    32: 102-110.","DOI":"10.1038\/leu.2017.179"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 D\u2019Agostino                            M,                                Zaccaria                            GM,                                Ziccheddu                            B                    <i>et al.<\/i> Early relapse risk in patients with newly diagnosed                    multiple myeloma characterized by next-generation sequencing. Clin Cancer Res.                    2020; 26: 4832-4841.","DOI":"10.1158\/1078-0432.CCR-20-0951"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Weinhold                            N,                                Ashby                            C,                                Rasche                            L                    <i>et al.<\/i> Clonal selection and double-hit events involving tumor                    suppressor genes underlie relapse in myeloma. Blood. 2016; 128:                    1735-1744.","DOI":"10.1182\/blood-2016-06-723007"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Walker                            BA,                                Mavrommatis                            K,                                Wardell                            CP                    <i>et al.<\/i> A high-risk, Double-Hit, group of newly diagnosed                    myeloma identified by genomic analysis. Leukemia. 2019; 33:                    159-170.","DOI":"10.1038\/s41375-018-0196-8"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Zojer                            N,                                K\u00f6nigsberg                            R,                                Ackermann                            J                    <i>et al.<\/i> Deletion of 13q14 remains an independent adverse                    prognostic variable in multiple myeloma despite its frequent detection by                    interphase fluorescence in situ hybridization. Blood. 2000; 95:                    1925-1930.","DOI":"10.1182\/blood.V95.6.1925"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Shaughnessy                            J                            Jr, Tian                            E,                                Sawyer                            J                    <i>et al.<\/i> Prognostic impact of cytogenetic and interphase                    fluorescence in situ hybridization\u2010defined chromosome 13 deletion in multiple                    myeloma: early results of total therapy II. Br J Haematol. 2003; 120:                    44-52.","DOI":"10.1046\/j.1365-2141.2003.03948.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Chiecchio                            L,                                Protheroe                            RKM,                                Ibrahim                            AH                    <i>et al.<\/i> Deletion of chromosome 13 detected by conventional                    cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006; 20:                    1610-1617.","DOI":"10.1038\/sj.leu.2404304"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Kiyota                            M,                                Kobayashi                            T,                                Fuchida                            S                    <i>et al.<\/i> Monosomy 13 in metaphase spreads is a predictor of poor                    long-term outcome after bortezomib plus dexamethasone treatment for                    relapsed\/refractory multiple myeloma. Int J Hematol. 2012; 95:                    516-526.","DOI":"10.1007\/s12185-012-1035-8"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Binder                            M,                                Rajkumar                            SV,                                Ketterling                            RP                    <i>et al.<\/i> Prognostic implications of abnormalities of chromosome                    13 and the presence of multiple cytogenetic high-risk abnormalities in newly                    diagnosed multiple myeloma. Blood Cancer J. 2017; 7:                        e600.","DOI":"10.1038\/bcj.2017.83"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Avet-Loiseau                            H,                                Gerson                            F,                                Magrangeas                            F                    <i>et al.<\/i> Rearrangements of the c-myc oncogene are present in 15%                    of primary human multiple myeloma tumors. Blood. 2001; 98:                    3082-3086.","DOI":"10.1182\/blood.V98.10.3082"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Garc\u00eda                            R,                                Chen                            W,                                Koduru                            P. Clinical                    impact of MYC abnormalities in plasma cell myeloma. Cancer Genet. 2018; 228-229:                    115-126.","DOI":"10.1016\/j.cancergen.2018.10.007"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Sekiguchi                            N,                                Ootsubo                            K,                                Wagatsuma                            M                    <i>et al.<\/i> Impact of C-Myc gene-related aberrations in newly                    diagnosed myeloma with bortezomib\/dexamethasone therapy. Int J Hematol. 2014;                    99: 288-295.","DOI":"10.1007\/s12185-014-1514-1"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Okada                            Y,                                Teramoto                            M,                                Tachi                            N                    <i>et al.<\/i> The prognostic impact of MYC gene-related abnormalities                    on multiple myeloma outcome through fluorescence in situ hybridization analysis.                    Acta Haematol. 2022; 145: 582-591.","DOI":"10.1159\/000521902"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/1\/64_23047\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T05:45:09Z","timestamp":1711777509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/1\/64_23047\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23047","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"23047"}}